Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
compound b
- Development stage
- Preclinical
- Lead developer
- University of Alberta
- Modality
- Small Molecules
01
Overview
Compound B is a small molecule designed to activate immune cells, with research suggesting increased production of T cells and cytokines when administered, potentially making it useful for cancer immunotherapy and chronic infections. It was developed by researchers at the University of Alberta, particularly by Prof. Khaled Barakat, and is still in the research and development phase. It is a derivative of a previously tested compound, modified for improved water-solubility and pharmacokinetic properties, which may allow it to cross the blood-brain barrier—a significant advantage for targeting central nervous system tumors[5].
Beyond the preview
Go deeper on compound b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on compound b.